Egypt · Delayed Price · Currency is EGP Ibnsina Pharma Statistics
Total Valuation
Ibnsina Pharma has a market cap or net worth of EGP 10.92 billion. The enterprise value is 34.54 billion.
| Market Cap | 10.92B |
| Enterprise Value | 34.54B |
Important Dates
The last earnings date was Tuesday, November 11, 2025.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | Oct 13, 2025 |
Share Statistics
Ibnsina Pharma has 1.01 billion shares outstanding.
| Current Share Class | 1.01B |
| Shares Outstanding | 1.01B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.01% |
| Owned by Institutions (%) | 23.67% |
| Float | 652.98M |
Valuation Ratios
The trailing PE ratio is 15.53 and the forward PE ratio is 8.97.
| PE Ratio | 15.53 |
| Forward PE | 8.97 |
| PS Ratio | 0.15 |
| PB Ratio | 4.38 |
| P/TBV Ratio | 4.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.54, with an EV/FCF ratio of -10.50.
| EV / Earnings | 49.14 |
| EV / Sales | 0.47 |
| EV / EBITDA | 9.54 |
| EV / EBIT | 10.37 |
| EV / FCF | -10.50 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 9.99.
| Current Ratio | 1.01 |
| Quick Ratio | 0.68 |
| Debt / Equity | 9.99 |
| Debt / EBITDA | 6.88 |
| Debt / FCF | -7.57 |
| Interest Coverage | 1.34 |
Financial Efficiency
Return on equity (ROE) is 40.22% and return on invested capital (ROIC) is 9.00%.
| Return on Equity (ROE) | 40.22% |
| Return on Assets (ROA) | 6.73% |
| Return on Invested Capital (ROIC) | 9.00% |
| Return on Capital Employed (ROCE) | 95.45% |
| Revenue Per Employee | 13.24M |
| Profits Per Employee | 127,817 |
| Employee Count | 5,500 |
| Asset Turnover | 2.36 |
| Inventory Turnover | 9.08 |
Taxes
In the past 12 months, Ibnsina Pharma has paid 80.98 million in taxes.
| Income Tax | 80.98M |
| Effective Tax Rate | 8.53% |
Stock Price Statistics
The stock price has increased by +59.97% in the last 52 weeks. The beta is 0.59, so Ibnsina Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | +59.97% |
| 50-Day Moving Average | 11.17 |
| 200-Day Moving Average | 9.57 |
| Relative Strength Index (RSI) | 45.67 |
| Average Volume (20 Days) | 4,754,622 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ibnsina Pharma had revenue of EGP 72.83 billion and earned 702.99 million in profits. Earnings per share was 0.70.
| Revenue | 72.83B |
| Gross Profit | 6.13B |
| Operating Income | 3.33B |
| Pretax Income | 948.87M |
| Net Income | 702.99M |
| EBITDA | 3.48B |
| EBIT | 3.33B |
| Earnings Per Share (EPS) | 0.70 |
Balance Sheet
The company has 1.28 billion in cash and 24.91 billion in debt, giving a net cash position of -23.63 billion or -23.44 per share.
| Cash & Cash Equivalents | 1.28B |
| Total Debt | 24.91B |
| Net Cash | -23.63B |
| Net Cash Per Share | -23.44 |
| Equity (Book Value) | 2.49B |
| Book Value Per Share | 2.47 |
| Working Capital | 265.44M |
Cash Flow
In the last 12 months, operating cash flow was -2.86 billion and capital expenditures -428.90 million, giving a free cash flow of -3.29 billion.
| Operating Cash Flow | -2.86B |
| Capital Expenditures | -428.90M |
| Free Cash Flow | -3.29B |
| FCF Per Share | -3.26 |
Margins
Gross margin is 8.42%, with operating and profit margins of 4.57% and 1.19%.
| Gross Margin | 8.42% |
| Operating Margin | 4.57% |
| Pretax Margin | 1.30% |
| Profit Margin | 1.19% |
| EBITDA Margin | 4.78% |
| EBIT Margin | 4.57% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.16, which amounts to a dividend yield of 1.48%.
| Dividend Per Share | 0.16 |
| Dividend Yield | 1.48% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 3 |
| Payout Ratio | 4.58% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.45% |
| Earnings Yield | 6.44% |
| FCF Yield | -30.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.16666.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.16666 |
Scores
Ibnsina Pharma has an Altman Z-Score of 2.59 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.59 |
| Piotroski F-Score | 5 |